IFNA2 and HIV infectious disease: We have previously shown that IFNα14, IFNα6, and IFNα17 significantly inhibited HIV replication in infected gut-derived lamina propria mononuclear cells (LPMCs), the earliest cellular targets during natural HIV infection, as well as peripheral blood mononuclear cells (PBMCs), whereas the clinically approved IFNα2 showed only moderate antiviral effects against HIV in both cell types (2, 10).